Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis - PubMed
Ann E Clarke 1 ,
Article ImagesReview
. 2021 Dec;51(6):1230-1241.
doi: 10.1016/j.semarthrit.2021.09.009. Epub 2021 Sep 30.
Affiliations
- PMID: 34710720
- DOI: 10.1016/j.semarthrit.2021.09.009
Free article
Review
Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis
Ann E Clarke et al. Semin Arthritis Rheum. 2021 Dec.
Free article
Abstract
Background: Malignancy is a potential comorbidity in patients with systemic lupus erythematosus (SLE). However, risk by malignancy type remains to be fully elucidated. We evaluated the risk of malignancy type in SLE patients in a systematic review and meta-analysis.
Methods: MEDLINE and EMBASE were searched from inception to July 2018 to identify observational studies that evaluated malignancy risk in adult SLE patients compared with the general population. Random-effects models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs). Heterogeneity was quantified using the I2 test.
Findings: Forty-one studies reporting on 40 malignancies (one overall, 39 site-specific) were included in the meta-analysis. The pooled RR for all malignancies from 3694 events across 80 833 patients was 1.18 (95% CI: 1.00-1.38). The risk of 24 site-specific malignancies (62%) was increased in SLE patients. For malignancies with ≥6 studies, non-Hodgkin lymphoma and Hodgkin lymphoma risk was increased >3-fold; myeloma and liver >2-fold; cervical, lung, bladder, and thyroid ≥1.5-fold; stomach and brain >1.3-fold. The risk of four malignancies (breast, uterine, melanoma, prostate) was decreased, whereas risk of 11 other malignancies did not differ between SLE patients and the general population. Heterogeneity ranged between 0% and 96%, and 63% were non-significant.
Interpretation: The risk of overall and some site-specific malignancies is increased in SLE compared with the general population. However, the risk for some site-specific malignancies is decreased or did not differ. Further examination of risk profiles and SLE patient phenotypes may support guidelines aimed at reducing malignancy risk.
Funding: AstraZeneca.
Systematic review registration: PROSPERO number: CRD42018110433.
Keywords: Cancer; Malignancy; Systematic Review With Meta-Analysis; Systemic Lupus Erythematosus.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest AC has received consulting fees from AstraZeneca, BMS, Exagen Diagnostics, and GSK. NP, ZM, JL, LN, SL, and NE have received personal fees from AstraZeneca during the conduct of the study and outside the submitted work. XW and VB are employees of AstraZeneca. BD is an employee and shareholder of AstraZeneca. ERH was an employee of AstraZeneca at the time of study.
Similar articles
-
Systemic lupus erythematous and malignancy risk: a meta-analysis.
Cao L, Tong H, Xu G, Liu P, Meng H, Wang J, Zhao X, Tang Y, Jin J. Cao L, et al. PLoS One. 2015 Apr 17;10(4):e0122964. doi: 10.1371/journal.pone.0122964. eCollection 2015. PLoS One. 2015. PMID: 25885411 Free PMC article.
-
Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond E. Yazdany J, et al. RMD Open. 2020 Sep;6(2):e001247. doi: 10.1136/rmdopen-2020-001247. RMD Open. 2020. PMID: 32900883 Free PMC article.
-
Ni J, Qiu LJ, Hu LF, Cen H, Zhang M, Wen PF, Wang XS, Pan HF, Ye DQ. Ni J, et al. Lupus. 2014 Mar;23(3):284-92. doi: 10.1177/0961203313520060. Epub 2014 Jan 15. Lupus. 2014. PMID: 24429300 Review.
-
Systemic lupus erythematosus and malignancies risk.
Mao S, Shen H, Zhang J. Mao S, et al. J Cancer Res Clin Oncol. 2016 Jan;142(1):253-62. doi: 10.1007/s00432-015-2032-0. Epub 2015 Aug 29. J Cancer Res Clin Oncol. 2016. PMID: 26319223
-
Malignancies in systemic lupus erythematosus: an update.
Ladouceur A, Clarke AE, Ramsey-Goldman R, Bernatsky S. Ladouceur A, et al. Curr Opin Rheumatol. 2019 Nov;31(6):678-681. doi: 10.1097/BOR.0000000000000648. Curr Opin Rheumatol. 2019. PMID: 31403485 Review.
Cited by
-
Ritter E, Itach T, Paran D, Gaskin A, Havakuk O, Ablin JN. Ritter E, et al. J Clin Med. 2024 Jul 25;13(15):4345. doi: 10.3390/jcm13154345. J Clin Med. 2024. PMID: 39124611 Free PMC article. Review.
-
Association between systemic lupus erythematosus and common female reproductive system malignancies.
Sirong C, Zhang K, Yang Y, Zhong Y, Sun P, Zanhong W. Sirong C, et al. Discov Oncol. 2024 Aug 9;15(1):341. doi: 10.1007/s12672-024-01218-3. Discov Oncol. 2024. PMID: 39120776 Free PMC article.
-
Kosałka-Węgiel J, Pacholczak-Madej R, Dziedzic R, Siwiec-Koźlik A, Spałkowska M, Milewski M, Zaręba L, Bazan-Socha S, Korkosz M. Kosałka-Węgiel J, et al. Rheumatol Int. 2024 Sep;44(9):1701-1713. doi: 10.1007/s00296-024-05623-3. Epub 2024 Jun 8. Rheumatol Int. 2024. PMID: 38850326 Free PMC article.
-
Wang L, Zhang Q, Shi N, Wang J, Song S, Yang H, Chen X. Wang L, et al. Front Oncol. 2024 Feb 21;14:1322598. doi: 10.3389/fonc.2024.1322598. eCollection 2024. Front Oncol. 2024. PMID: 38450194 Free PMC article.
-
Wang K, Wang S, Ding Y, Kou Z, Jiang B, Hou S. Wang K, et al. Int J Gen Med. 2024 Feb 28;17:705-723. doi: 10.2147/IJGM.S448720. eCollection 2024. Int J Gen Med. 2024. PMID: 38435117 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical